Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017038909) HETEROCYCLIC COMPOUNDS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/038909 International Application No.: PCT/JP2016/075585
Publication Date: 09.03.2017 International Filing Date: 25.08.2016
IPC:
C07D 498/04 (2006.01) ,A61K 31/5383 (2006.01) ,A61P 29/00 (2006.01) ,A61P 37/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
498
Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
535
having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
5375
1,4-Oxazines, e.g. morpholine
5383
ortho- or peri-condensed with heterocyclic ring systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29
Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
Applicants:
TAKEDA PHARMACEUTICAL COMPANY LIMITED [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410045, JP
Inventors:
KOUL, Summon; IN
KURHADE, Suresh; IN
NAIK, Keshav; IN
SALUNKHE, Videsh; IN
KULKARNI, Rakesh; IN
PARDESHI, Vishwajeet; IN
BHUNIYA, Debnath; IN
KULKARNI, Bheemashankar; IN
MOOKHTIAR, Kasim Abbaas; IN
Agent:
TAKASHIMA, Hajime; Meiji Yasuda Seimei Osaka Midosuji Bldg., 1-1, Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410044, JP
Priority Data:
2707/DEL/201528.08.2015IN
Title (EN) HETEROCYCLIC COMPOUNDS
(FR) COMPOSÉS HÉTÉROCYCLIQUES
Abstract:
(EN) The present invention provides a heterocyclic compound a TLR7 and/or TLR9 and/or TLR-7/8/9 and/or TLR-7/8 and/or TLR-7/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases and/or inflammatory diseases and the like, in particular, acute decompensated heart failure, non-alcoholic steatohepatitis (NASH), IgA nephropathy, Duchenne muscular dystrophy (DMD), systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, transplant rejection and graft-versus-host disease, hepatocellular carcinoma (HCC) and the like. The present invention is a compound represented by the formula (1) : wherein each symbol is as described in the specification, or a salt thereof.
(FR) La présente invention décrit un composé hétérocyclique une action inhibitrice de TLR7 et/ou TLR9 et/ou TLR-7/8/9 et/ou TLR-7/8 et/ou TLR-7/9, qui est utile comme agent de prophylaxie ou de traitement des maladies auto-immunes et/ou des maladies inflammatoires et similaires, en particulier, l’insuffisance cardiaque aiguë décompensée, la stéatohépatite non alcoolique (NASH), la néphropathie IgA, la dystrophie musculaire de Duchenne (DMD), le lupus érythémateux systémique, le syndrome de Sjogren, l’arthrite rhumatoïde, le psoriasis, la maladie inflammatoire chronique intestinale, l’asthme, le diabète de type 1, la myasthenia gravis, le dysfonctionnement hématopoïétique, les malignités des cellules B, le rejet de transplantation et la maladie du greffon versus l’hôte, le carcinome hépatocellulaire (HCC) et similaires. La présente invention est un composé représenté par la formule (1) : dans laquelle chaque symbole est tel que décrit dans la description, ou un sel de ce dernier.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)